Postherpetic Neuralgia
📧 Sign up to get email alerts when something new happens for Postherpetic Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-06-08FDA Approved: GABAPENTIN — Supplemental Application (Acella Pharmaceuticals, LLC)
FDA approved a supplemental application for gabapentin from Acella Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2017-05-01Clinical Trial Update: Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain [Phase 1, Phase 2]
A clinical trial update on a capsaicin patch for peripheral neuropathic pain, combining Phase 1 and Phase 2 cohorts, which has completed.
-
CLINICAL_TRIALS research · 2017-04-19Clinical Trial Update: Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia [NA]
A clinical trial evaluating whether early oxycodone use during the acute phase of herpes zoster can prevent postherpetic neuralgia; the stat…
-
CLINICAL_TRIALS research · 2017-04-11Clinical Trial Update: Involvement of Reorganization of Cerebral Functional Connectivity in the Process of Transition to Postherpetic Neuralgia
This clinical trial update investigates how changes in cerebral functional connectivity may relate to the transition to postherpetic neuralg…
-
FDA approval · 2017-03-24FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA supplemental approval for Neurontin (gabapentin) by Parke-Davis Division of Pfizer Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-03-24FDA Approved: GABAPENTIN — Original Application (Rising Pharma Holdings, Inc.)
FDA approves Rising Pharma's original application for gabapentin, a generic version of the anticonvulsant, for the treatment of epilepsy (pa…
-
FDA label_change · 2017-03-06FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
FDA approved a supplemental application for Gralise (gabapentin) filed by Almatica Pharma LLC, resulting in a label change for the product.
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve [Phase 2]
A Phase 2 trial of Civamide Nasal Solution for postherpetic neuralgia of the trigeminal nerve was terminated, and the study results were pos…
-
CLINICAL_TRIALS research · 2017-02-28Clinical Trial Update: Regional-anaesthesiological Infiltration Techniques for the Management of Chronic Pain: a Retrospective Study
A retrospective study update evaluating regional anaesthesiological infiltration techniques for managing chronic pain, including trigeminal …
-
CLINICAL_TRIALS trial_result · 2017-02-13Clinical Trial Update: Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia [Phase 2]
An update on a Phase 2 clinical trial evaluating a civamide patch for treatment of postherpetic neuralgia and post-incisional neuralgia.
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: Effects of Pennsaid on Clinical Neuropathic Pain [NA]
This clinical trial update reports completion and posted results of a study evaluating Pennsaid for neuropathic pain conditions such as neur…
-
FDA approval · 2016-12-22FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Division of Pfizer Inc.
-
FDA approval · 2016-11-08FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for gabapentin submitted by BluePoint Laboratories.
-
FDA approval · 2016-11-08FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for gabapentin (ANDA078428).
-
CLINICAL_TRIALS trial_result · 2016-08-16Clinical Trial Update: Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia [Phase 3]
Phase 3 trial update reporting efficacy and safety data for a pregabalin sustained release tablet in postherpetic neuralgia.
-
CLINICAL_TRIALS research · 2016-06-10Clinical Trial Update: Comparison of the Efficacy of the Ultrasound With Fluoroscopy in Guidance of Lumbar Sympathetic Block [NA]
This clinical trial compares ultrasound guidance versus fluoroscopy guidance for lumbar sympathetic block to evaluate efficacy and potential…
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) [Phase 2]
A Phase 2 study evaluating JNJ-42160443 for neuropathic pain conditions including postherpetic neuralgia and post-traumatic neuralgia has be…
-
FDA approval · 2016-03-17FDA Approved: LIDOCAINE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for lidocaine patch 5% (Lidocaine) by Endo USA, Inc.
-
FDA approval · 2016-03-14FDA Approved: GABAPENTIN — Original Application (Ajenat Pharmaceuticals LLC)
FDA approves a new generic gabapentin product (Original Application) by Ajenat Pharmaceuticals LLC under anANDA; the approval covers the sam…
-
CLINICAL_TRIALS trial_result · 2016-03-11Clinical Trial Update: Botulinum Toxin in Peripheral Neuropathic Pain [Phase 4]
A Phase 4 clinical trial evaluating botulinum toxin for peripheral neuropathic pain has completed.
-
FDA approval · 2016-02-24FDA Approved: QUTENZA — Supplemental Application (Averitas Pharma Inc)
FDA approved a supplemental application for QUTENZA (capsaicin) submitted by Averitas Pharma Inc.
-
FDA approval · 2016-02-18FDA Approved: GABAPENTIN — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original generic application for gabapentin from ScieGen Pharmaceuticals, Inc., establishing a generic version of gabapenti…
-
FDA approval · 2016-02-04FDA Approved: GABAPENTIN — Original Application (Creekwood Pharmaceuticals LLC)
FDA approved Creekwood Pharmaceuticals LLC's gabapentin under an Abbreviated New Drug Application, authorizing the generic product's market …
-
FDA approval · 2016-02-03FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approves a supplemental application for gabapentin from Exelan Pharmaceuticals, Inc., granting regulatory approval for this generic prod…
-
CLINICAL_TRIALS trial_result · 2016-01-13Clinical Trial Update: Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia [Phase 3]
Phase 3 trial assessing safety and efficacy of once-daily controlled-release pregabalin for postherpetic neuralgia has completed with result…